EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies

Lung cancer is the leading cause of cancer incidence and mortality, with an estimated 2 million diagnosed cases and 1.8 million deaths per year reported worldwide [1]. In 2022, an estimated 0.87 million new cases and 0.76 million deaths of lung cancer were reported in China [2]. Non –small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85 % of all cases [3–5]. Over the past decade, advances in our understanding of cell signaling pathways that control cell survival have identified genetic and epigenetic alterations, which promote cell prolif eration and tumorigenesis.

Source: Cancer Treatment Reviews - August 6, 2023 Category: Cancer & Oncology Authors: Qianming Bai, Jialei Wang, Xiaoyan Zhou Tags: Anti-tumour Treatment Source Type: research